Clinical trials
Colorectal Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting colorectal cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,490 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06873269Recruiting
Holmium-166 radiation therapy for liver cancer
This trial tests a radiation treatment for liver cancer that cannot be removed with surgery or ablation. Tiny beads containing Holmium-166 are injected into the liver's blood supply to target the tumor directly.
BrusselsAges 18 years+ - NCT06669117RecruitingPhase 1/Phase 2
VERT-002 for solid tumors with MET changes
This trial tests a new drug, VERT-002, for people with advanced solid tumors, including non-small cell lung cancer (NSCLC), that have specific changes in the MET gene. It aims to see if the drug can shrink tumors or stop them from growing when other treatments haven't worked or aren't available.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06859684RecruitingPhase 2
Triple therapy for advanced bile duct cancer of the liver
This trial tests a combination of three treatments for people with advanced bile duct cancer that cannot be removed by surgery or has spread. The treatments include a chemotherapy infusion directly into the liver artery (HAIC), an immunotherapy drug (durvalumab), and a targeted therapy pill (lenvatinib). It aims to see if this triple therapy can shrink or control the cancer better than standard treatments.
Chengdu, SichuanAges 18–75 - NCT06855771RecruitingPhase 2
Study of navlimetostat alone or with izalontamab for advanced lung cancer
This trial tests a new drug, navlimetostat, either by itself or combined with another drug, izalontamab, for people with advanced non-small cell lung cancer that has a specific genetic change (MTAP loss). The goal is to see if these treatments can help shrink tumors or slow cancer growth.
Anchorage, AlaskaAges 18 years+ - NCT06826313RecruitingPhase 1
Virus treatment for advanced solid tumors
This trial tests an intravenous virus treatment (VRT106) for people with advanced solid tumors that have stopped responding to standard therapies. The goal is to see if the virus can target and help control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06831136RecruitingPhase 2
Endoscopic ultrasound ablation with immunotherapy for pancreatic cancer
This trial tests a procedure that uses sound waves to heat and destroy part of the tumor, combined with an immunotherapy drug called pembrolizumab (Keytruda) that helps your immune system fight the cancer. It is for people with pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body.
Houston, TexasAges 18 years+ - NCT06829355RecruitingPhase 2
Thymalfasin plus triple therapy for advanced colorectal cancer
This trial tests a combination of three drugs plus thymalfasin, an immune-boosting medicine, for people whose advanced colorectal cancer has not responded to at least two prior treatments. It's designed specifically for the common type of colorectal cancer (pMMR/MSS) to see if adding this immune therapy can help.
Beijing, ChinaAges 18–75 - NCT06833229Recruiting
Can a PET scan predict if immunotherapy is working?
This study uses a special PET-CT scan early in your treatment to see if immunotherapy (with or without chemotherapy) is working against your advanced lung cancer. The goal is to find out faster if the treatment is helping.
NiceAges 18 years+ - NCT06823427RecruitingPhase 2
9MW2821 with or without immunotherapy for advanced urothelial cancer
This trial tests a combination of an investigational drug (9MW2821) with an immunotherapy (toripalimab) against 9MW2821 alone for people with advanced urothelial cancer who have not yet received any systemic treatment. The goal is to see if the combination works better than the single drug.
Changsha, HunanAges 18–80 - NCT06805825RecruitingPhase 1
Study of NN3201 for advanced cancers with c-Kit
This trial tests a new drug, NN3201, that targets a protein called c-Kit found on some cancer cells. It may be an option for people with certain advanced solid tumors, including GIST, small cell lung cancer, or other c-Kit-positive cancers, who have already tried standard treatments or cannot take them.
Ann Arbor, MichiganAges 18 years+ - NCT06808685Recruiting
Study of Elovie for advanced colorectal cancer
This study looks at how well a biosimilar version of bevacizumab (Elovie) works in people with advanced colorectal cancer that has spread and cannot be surgically removed. It aims to see if Elovie is safe and effective when used as the first treatment for this cancer.
Vitória, Espírito SantoAges 18 years+ - NCT06797297RecruitingPhase 2
Study of IBI363 vs pembrolizumab for advanced mucosal or acral melanoma
This trial tests a new drug, IBI363, compared to the standard drug pembrolizumab (Keytruda) for people with advanced mucosal or acral melanoma who have not had treatment before. It aims to see if IBI363 works better or as well as the usual treatment.
Hefei, AnhuiAges 18 years+ - NCT05787197Recruiting
Blood test to guide treatment after colon cancer liver surgery
This trial studies a blood test (called ctDNA) in people with colon cancer that has spread to the liver and is being removed with curative surgery. The goal is to see how the blood test can help with planning and improving treatment after surgery.
BesançonAges 18 years+ - NCT06767800RecruitingPhase 2
Study of TQB2102 with immunotherapy for HER2-positive gastroesophageal cancer
This trial tests a new combination of drugs (TQB2102, benmelstobart, and pembrolizumab) with or without chemotherapy for people with HER2-positive gastroesophageal cancer that cannot be removed by surgery or has spread. It aims to see if this combination is more effective than current treatments.
Fuyang, AnhuiAges 18–75 - NCT06770270RecruitingPhase 2
Immunotherapy with radiation and chemo before rectal cancer surgery
This trial tests adding an immunotherapy drug (pucotenlimab) to standard radiation and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see if this combination can shrink the tumor more effectively and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT06770452RecruitingPhase 2
HRS-4642 combo for first-line advanced pancreatic cancer
This trial tests a new targeted drug (HRS-4642) combined with nimotuzumab and chemotherapy for people with advanced pancreatic cancer that has a specific gene change called KRAS G12D. It's for those who haven't had treatment for advanced disease yet.
Hangzhou, ZhejiangAges 18–75 - NCT06751329RecruitingPhase 1/Phase 2
Study of DM002 for advanced solid tumors
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT06742892RecruitingPhase 2
Study of HLX43 for advanced liver cancer after standard treatment fails
This trial tests a new drug, HLX43, for people with advanced liver cancer (HCC) that has worsened or caused intolerable side effects after standard treatments like immunotherapy or targeted therapy. The goal is to see if HLX43 can help when other options have stopped working.
Hunan, HunanAges 18–75 - NCT06745908RecruitingPhase 3
New drug combo for lung cancer after immunotherapy stops working
This trial tests a new drug combination (N-803 and tislelizumab with chemotherapy) for people whose lung cancer stopped responding to standard immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Springdale, ArkansasAges 18–90 - NCT06718621RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests an experimental drug called BL-M08D1 for people with solid tumors that have spread or cannot be removed by surgery and have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06720987RecruitingPhase 1
KQB365 for advanced solid tumors with KRAS mutations
This trial tests a new drug called KQB365, alone or with other drugs, for people with advanced solid tumors that have a specific KRAS mutation (G12C or G12S). It aims to see if the treatment is safe and effective.
Phoenix, ArizonaAges 18 years+ - NCT06705127RecruitingPhase 2
Radiation, chemo, and immunotherapy for HR+ breast cancer
This trial tests if giving radiation first, then chemo with an immunotherapy drug called Toripalimab, can help treat a certain type of breast cancer that has not spread to other organs. It is for people with hormone receptor positive, HER2 negative breast cancer that is growing fast.
Hangzhou, ZhejiangAges 18–75 - NCT06645236Recruiting
Testing for a specific KRAS mutation in tumor tissue
This study tests your tumor tissue for a specific change in the KRAS gene called G12C. Finding this mutation may help guide treatment options for certain cancers.
Manchester, ManchesterAges 18 years+ - NCT06650163RecruitingPhase 1
New imaging test for brain tumor surgery planning
This trial tests a new kind of PET scan that uses a special tracer (Zr-89 crefmirlimab berdoxam) to help doctors see brain tumors more clearly before surgery. If you are scheduled to have your brain tumor removed, this scan may give your surgeon extra information to guide the operation.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Colorectal Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colorectal cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,490 recruiting colorectal cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colorectal cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colorectal cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced Colorectal Cancer
- Lung Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- Metastatic Colorectal Cancer
- Locally Advanced Rectal Cancer
- Metastatic Colorectal Cancer (CRC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.